Introduction
Calpain (clan CA, family C2, EC 3.4.22.18) comprises a family of Ca 2þ -dependent neutral cysteine proteases. At least 15 gene products of the family are known in humans (1-3), including l-calpain (calpain 1) and m-calpain (calpain 2), termed conventional calpains, ubiquitously expressed in human tissues, and other tissue-specific isoenzymes. They are involved in a number of cellular events, such as cell proliferation and differentiation, gene expression, cytoskeleton reorganization and motility (1, 3, 4) . In the last decade, an increasing interest also focused the involvement of calpain in apoptotic death of tumor cells. However, conflicting results have shown either a promoting or a protective role, particularly depending on the concomitant involvement of the cross talking machinery of caspases (5) .
In human metastatic melanoma cells, we have recently demonstrated a key contribution of conventional calpains in apoptotic cell death induced by cisplatin: calpains are activated both in apoptotic cells and, very early, in still viable cells, whereas other typical features of apoptosis are still absent, and calpain inhibition affords a significant protection from apoptosis in several human melanoma cell lines. Such a protective effect is correlated with a novel mechanism, operating upstream to signaling pathways of apoptosis, which is the downregulation of cisplatin-induced p53 activation (6) .
At variance with ubiquitous calpains 1 and 2, calpain 3 (p94) is a family member considered muscle specific. Although its physiological role is still unclear even in muscle cells, calpain 3 seems to be crucial for muscle cell homeostasis, as demonstrated both in models of tumor-induced cachexia (7) and, mainly, in the limb-girdle muscular dystrophy type 2A (or calpainopathy), characterized by different calpain 3 point mutations and by muscle hypotrophy, hypoplasy and myonuclear apoptosis (8, 9) . The protein structure of calpain 3 (3, 10) differs from that of conventional calpain in three specific sequences: (i) NS, an N-terminal sequence of 47 amino acids; (ii) IS1, located inside the catalytic domain II and containing two autolysis sites; (iii) IS2, located between domain III and IV and containing both a putative nuclear localization sequence (NLS) and a connectin (titin)-binding site. A subfamily of shorter splicing variants of p94 has been recently reported in non-muscle human tissues, including an exon 6À/exon 15À isoform in lymphocytes (11) , and, more interestingly, two ubiquitous isoforms, in which the 5# sequence, corresponding to the last four exons (exons 21-24) of the neutral a-glucosidase C (GANC), lacks the authentic NS-encoding exon 1 (12) .
Two recent publications, showing a link between the musclespecific p94 calpain and melanoma cells, stimulated our attention.
In particular, the authors demonstrated an ectopic expression of calpain 3 higher than in other tumor types (13) and a calpain 3 downregulation, along with cytostasis and apoptosis, in melanoma cells sensitive to interferon-c (14) .
In the light of these observations and of our previous findings showing an involvement of conventional calpains in apoptosis of human melanoma cells, we were interested in investigating calpain 3 (and related isoforms) transcripts and protein expression in different melanoma cell lines; the study has been also performed in melanoma cells undergoing apoptosis by cisplatin poisoning. Encouraging results obtained in melanoma cell lines prompted us to further explore calpain 3-related gene expression in human biopsies of normal nevi, dysplastic nevi, primary melanomas and metastases, in an attempt to identify a possible correlation with melanoma progression.
Materials and methods
Cell lines, culture conditions and treatments Four human cell lines derived from cutaneous melanomas were used in this study: Me665/2/21, kindly provided by Dr Zunino (Istituto Nazionale Tumori, Milan), and HT-144, SK-Mel-28 and SK-Mel-5 purchased from the American Type Culture Collection, Rockville, MD. With the exception of SK-Mel-28, a primary vertical growth phase melanoma (VGPM), they all are metastatic tumors.
Cells were cultured at 37°C, under 95:5% CO2 in a humidified atmosphere, using the following media (Sigma, Milan, Italy): RPMI 1640 medium for Me665/2/21 cells, Mc Coy's 5A medium for HT-144 cells and Eagle's minimal essential medium with Earle's balanced saline solution (adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids and 1 mM sodium pyruvate) for SK-Mel-28 and SK-Mel-5. All media were supplemented with 10% heat-inactivated fetal calf serum (Invitrogen, Milan, Italy), 2 mM Lglutamine (Sigma) and 50 mg/l gentamycin. Cells were routinely harvested by phosphate-buffered saline (PBS)-ethylenediaminetetraacetic acid (EDTA) (0.2 g/l) and reseeded before reaching confluence.
For experiments, cells were seeded at 3-4 Â 10 6 cells on 150 cm 2 plastic dishes (Sarstedt, Newton, NC) overnight, whereupon the medium was changed. Cells were treated for 24 or 48 h with cisplatin [cis-platinum(II) diammine dichloride] (Sigma) at the concentration of 1 lg/ml, unless otherwise stated, at the constant ratio of 20 nmoles per 10 6 cells. The conventional calpains' inhibitor, calpeptin (30 lM), was added to culture medium at 0 time.
For cisplatin-treated samples at 48 h, we harvested and analyzed the population of still adhering cells in the monolayer separately from the population of detached cells. Adherent cells were gently detached by PBS-EDTA treatment, and both adherent and floating cell suspensions were counted in a Bürker chamber. The apoptotic response was evaluated as percentage of floating cells on total cells of each sample; as described previously by us in the same experimental model (6, 15) , such a percentage strictly correlates with the rate of apoptotic cell death, as measured by biochemical and morphological parameters, whereas still adhering cells show no or minor signs of cell death.
Western blot analysis
Whole-cell extracts were prepared as follows: adherent and floating cells were separately harvested and lysed for 30 min on ice in lysis buffer containing 100 mM N-[2-hydroxyethyl]piperazidine-N#-[2-ethanesulfonic acid], pH 7.5, 10% sucrose, 1 mM EDTA, 1% Nonidet-40 (Sigma), supplemented with 10 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and the protease inhibitors cocktail (Sigma). After sonication for 10 s, the insoluble material was removed by centrifugation. Biopsies of human muscle were quickly minced on ice and homogenized in the above lysis buffer at 4°C using a syringe with a 20 gauge needle. Protein concentration was determined by using Bradford method.
Nuclear and post-nuclear fractions were prepared as described by Kyo et al. (16) . In total, 3 Â 10 6 cells were harvested, washed in ice-cold PBS and resuspended in 150 ll of the following buffer: 10 mM N- [2- hydroxyethyl]piperazidine-N#-[2-ethanesulfonic acid] (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM ethylene glycol bis-(b-aminoethyl ether) N,N,N#,N#-tetraacetic acid, supplemented with 1mM phenylmethylsulfonyl fluoride and the protease inhibitors cocktail. After swelling on ice, 9.4 ll of 10% Nonidet-40 (Sigma) was added, the homogenate was vigorously vortexed for 10 s and then centrifuged at 12 000 r.p.m. for 60 s at 4°C. The supernatant was recovered as post-nuclear extract. The pellet (nuclear fraction) was washed, resuspended in 100 ll of the above lysis buffer and sonicated, and the insoluble material was removed by centrifugation.
Aliquots (40-60 lg protein) of cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (8%) at 200 V, followed by electroblotting to nitrocellulose membrane (Protan BA 85, 0.45 lm; Schleicher and Schuell, Keene, NH) for 30 min at 150 mA (semidry Transblot Cell, Pharmacia Biotech, Piscataway, NJ). After 1 h in blocking solution (PBS containing 0.05% Tween-20 and 10% dried non-fat milk), membranes were probed with primary antibodies anti-calpain 3 (dilution 1:3000) overnight at 4°C. The primary antibodies (Abcam, Cambridge, UK) were rabbit polyclonal antibodies to domain III (ab38963), against IS2 inset, and to domain II (ab38962), against IS1 inset. Anti-rabbit horseradish peroxidase-conjugated IgGs (Sigma) were used as secondary antibody. Protein bands were visualized by a chemiluminescence detection kit (Pierce, Celbio, Milan, Italy). An equivalent protein loading was confirmed each time by Ponceau red protein staining on membrane prior to primary antibody. Densitometric analysis was performed by Versadoc Model 1000 (Bio-Rad, Hercules, CA). Membranes were also probed with secondary antibody alone, to rule out possible unspecific bands.
Immunocytochemistry
Immunocytochemical analysis was performed in Me/665/2/21 melanoma cells. Cells were grown on 18 mm diameter cover glasses and fixed with cold acetone (À20°C) for 5 min at 4°C. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 5 min, and non-specific immune-binding sites were blocked by incubation with 1% bovine serum albumin in PBS for 30 min. Cells were then incubated overnight at 4°C with anti-calpain 3 primary antibodies (anti-IS1 or anti-IS2, the same used for western blots) at dilution of 1:250 in 1% bovine serum albumin/PBS. After PBS wash (2 Â 5 min), cells were incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Sigma) at dilution of 1:250 in 1% bovine serum albumin/PBS for 1 h. After PBS wash (2 Â 5 min), cells were stained with 3,3-diaminobenzidine dihydrochloride (DAB-tablets; Sigma) as chromogenic substrate and counterstained with Meyer's hematoxylin. Cells were dehydrated with increasing solutions of ethanol, cleared with xylol and mounted with mounting medium Eukitt (Fluka; Sigma-Aldrich Corp., Milan, Italy). Positivity to calpain 3 variants was revealed by a brown staining. Negative controls were performed in the same conditions, without the primary antibodies. Photographs were taken in a Leitz DMRB photomicroscope (Leica Microsystem, Milano, Italy), equipped with Application Suite AF software.
Human biopsies
Sixty-one consecutive cutaneous melanocytic lesions, in which there was diagnostic consent among expert pathologists, based on current diagnostic criteria (17), entered our study. There were 11 benign nevi, 6 dysplastic nevi and 7 melanomas in radial growth phase (RGPM; median thickness: 0 mm; range: 0-0.35 mm), 21 VGPMs (median thickness: 1.54 mm; range: 0.38-6.54 mm) and 16 melanoma metastases. VGPM included eight level III (neoplastic infiltration limited to the superficial, papillary dermis) and 13 level IV (neoplastic infiltration extended to the deep, reticular dermis) melanomas. There were 13 cutaneous, 2 cerebral and 1 regional lymph node metastases. In all cases, at the surgical excision of the lesions, some fragments were immediately harvested and frozen in liquid N 2 for gene expression analysis. Frozen fragments of pectoral muscle removed during radical mastectomy for breast cancer were also analyzed for western blot analysis and for polymerase chain reaction (PCR) analysis. All patients provided written informed consent. The study was approved by the appropriate local ethics committee and was performed according to the declaration of Helsinki of 1996.
RNA isolation and complementary DNA preparation Total RNA was extracted from $5 Â 10 6 melanoma cells or from frozen human biopsies using RNAeasy Plus Mini-Kit (Qiagen GmbH, Milan, Italy) or Trizol reagent (Invitrogen), respectively, according to the manufacturer's protocol. The quality of the RNA samples was assessed in agarose gel electrophoresis and ethidium bromide staining. RNA concentration was determined by measuring the absorbance at 260 nm. Total RNA was stored at À80°C until using. For complementary DNA (cDNA) synthesis, 2-5 lg of total RNA was reverse transcribed using Transcriptor First Strand cDNA Synthesis Kit (Roche, Monza, Italy), according to the manufacturer's instructions, and the cDNA products were stored at À20°C.
PCR analysis and sequencing
PCRs were performed using Taq DNA Polymerase (Roche) and the above cDNA as templates. Primers used, synthesized by Roche, are listed in Table I . PCR products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining.
PCR products from melanoma cell lines cDNA were sequenced by BMRGenomics (Padua, Italy) using Sanger method with Genome Sequencer FLX (Roche). Sequence analysis was made using Chromas 2.33 (Technelysium Pty Ltd., Eden Prairie, MN) and Vector NTI 10 (Invitrogen). The sequences of hMp78 and hMp84 have been deposited in GenBank, under accession no. EU791850 and EU791851.
Real-time PCR analysis
A relative quantification of hMp78 and hMp84 messenger RNA (mRNA) expression normalized to the endogenous reference gene b-actin was performed by real-time PCR, using the DNA Engine Opticon 2 System (MJ Research, Celbio, Milan, Italy) and SYBR GreenER qPCR Supermix Universal (Invitrogen) as amplification and detection system. The primers used are indicated in position no. 4 and 5 of Figure 2 ; they amplify the IS2-coding region, shared by hMp78 and hMp84, thus giving a cumulative information of both variants. Thermocycling conditions were 10 min at 95°C, followed by 45 cycles of denaturation (94°C for 20 s), annealing (55°C for 20 s) and extension (72°C for 20 s). All samples were analyzed in triplicate and the results were represented by Ct parameter (threshold cycle number). Gene expression values of biopsies were expressed by 2
DCt , obtained by a slightly modified 2 ÀDDCt data analysis method (18) , where DCt is the difference between the Ct value of hMp78/hMp84 and the mean Ct value of the reference gene. The highest 2 DCt value corresponds to the lowest nucleic acid copy number in the sample. Gene expression values of cultured treated cells were expressed as fold change over untreated cells at 0 time by 2 ÀDDCt parameter. Table I . Primers used in this study Name Sequence (5# / 3#) Position in Figure 2 5# -NS  ATGCCGACCGTCATTAGC  1  3#-D4  TCAGGCATACATGGTGAGCTG  hUpS2  GGAATGAGTTGGCAAATCAG  3  5#-IS2  CGTGGATCGGCCAGTGAAAAA  4  3#-IS2  CTCTGACTCCTGGTCCAC  5  5#-IS1  CATGACCTATGGAACCTCTC  6  3#-IS1  GGTCGGTCTTTCATCTGAG  7  5#-IIA  TTGATGGAGCCAACAGAACTGAC  8  3#-D3  TAGGTGGAGGGCACGATGAC  9  5#-D3  GCCGATGCTCTGCAGTCTGA  10  3#-IIB  TGTCCACAAAGCTCCAGTCCTTC 
Results
Identification of novel splice variants of human skeletal muscle calpain 3 (p94) in human melanoma cells On the basis of amplification ( Figure 1A ) and sequencing of a region coding for IS2 inset of muscle calpain 3 (p94), we demonstrated that in all melanoma cell lines examined, the transcript is always present and the band corresponds to that of human muscle. However, all attempts to amplify the NS-encoding exon 1 (i.e. the typical region of p94, see Figure 2 ) failed (data not shown). On the contrary, when we used a sense primer on exon AX2, just upstream to exon 1 [according to the exon splicing scheme of (12) for hUp84], and an antisense primer downstream IS1 sequence ( Figure 1B) , the PCR analysis was successful and all melanoma cell lines showed a band (880 bp) of the expected molecular size and with an nucleotide sequence identical to human muscle. A shorter transcript was also present (745 bp), showing an splicing out of exon 6, with preservation of the translation frame; this variant, never described up to now in any normal or tumor cell, potentially gives a protein that lacks the entire IS1 insert (amino acids 268-315).
By sequence analysis of the entire cDNA (primers used are listed in Table I ), we have identified two novel variants of p94/calpain 3 subfamily expressed in human melanoma cells, termed by us hMp84 and hMp78 (human Melanoma, p84 or p78 to indicate their deduced molecular mass), and deposited in GenBank. In summary, hMp84 resembles the ubiquitous hUp84 with the addition of exon 15 coding for NLS, that is exclusively present in the canonical muscle-specific isoform p94, and hMp78 is an atypical hUp84, containing exon 15 but lacking exon 6 ( Figure 2 ).
Protein expression and mRNA of the p94 variants hMp84 and hMp78 in control and cisplatin-treated melanoma cells It is well known that p94, due to its rapid autolysis, is extremely unstable, both in muscle cell extracts (19) and in overexpressing systems (20) ; less is known about the single or combined contribution of the specific sequences on such instability both in vivo and in vitro. The binding of IS2 with the sarcomeric protein connectin in muscle cells has been shown to protect p94 from autolytic degradation in vivo (21) . In non-contractile cells, where connectin is virtually absent or very low, or during the invasive purification/extraction procedures, the recovery of the full-length protein is hard to obtain even in muscle cells. Furthermore, it has been shown that IS1 region acts as an internal pro-domain: its removal by intra-and intermolecular reactions cleaves the full-length enzyme and makes the reconstituted active site available for hydrolysis of substrates and accessible to inhibitors (22, 23) . Thus, the early view of p94 degradation is now regarded as p94 activation. Supporting the role of IS1 as a pro-domain, the authors also report that p94 isoform devoid of IS1 prove to be stable and enzymatically active in vitro, not so crucial for protein stability and activity seems to be the NS region. Consistently with the above observations on p94 instability, in melanoma cell lines western blot analysis performed with anti-IS2 antibody ( Figure 1C ) revealed the absence of any full-length protein and the presence of a unique band of $62 kDa, probably corresponding to the C-terminal moiety from domain IIb to domain IV, as described for p94 of human muscle cells (19) .
Experiments have been also performed on Me665/2/21 melanoma cells treated with cisplatin, an experimental model of apoptotic cell death well known in our laboratory (6, 15) . In these experiments (Table IIa) , the above described peptide of $62 kDa increased in still adhering and viable treated cells compared with control cells, whereas it remained at control levels in floating, apoptotic cells. In samples treated with cisplatin plus calpeptin, an inhibitor of conventional calpains confirmed to protect from cell death (Table IIb) , p62 level did not increase over that of control cells, rather markedly decreased in floating, frankly apoptotic cells. In cisplatin-treated cells, p62 increased in still viable cells proportionally to the amount of the apoptotic trigger (and proportionally to the apoptotic response) ( Figure 3A) ; interestingly, such an increase was also observed with a lower cisplatin concentration (0.4 lg/ml), at which no sign of cell death but only cell proliferation block was evident. The increase of the IS2-containing peptide, as revealed by western blot, is accompanied by mRNA upregulation in still viable cells of cisplatin-treated samples compared with control cells (Table IIc) , as measured by real-time PCR. In particular, the lower dose of cisplatin was the most effective for inducing the transcription of both isoforms; on the contrary, at the higher apoptogenic dose, at which the proteolytic events (increase of p62 peptide) were more pronounced, the whole transcriptional machinery is remarkably impaired and no increased transcription of both isoforms was observed.
Proteolytic cleavage and intracellular localization of hMp84 and hMp78
To evaluate the expression and the proteolytic patterns of both isoforms, melanoma cell extracts were probed with anti-IS1 and anti-IS2 antibodies, compared on the same erased membranes. With anti-IS1 antibody ( Figure 3B ), a major band of $70 kDa (band B) was constantly detected. A minor band of $84 kDa (band A), probably corresponding to the full-length hMp84, was also present, but not in all experiments; this can be due to the intrinsic instability of such protein both in vivo inside the cells and during the extraction procedures. By using anti-IS2 antibody (Figure 3C ), the latter band of $84 kDa was never detectable, probably depending on the lower affinity of this antibody for a protein poorly represented in the uncleaved form. The absence of band B suggests that this peptide (IS1þ/IS2À) of $70 kDa could derive from a cleavage of hMp84 at exon 14 just upstream IS2 insert (24) . The p62 protein (band C) is present, indicating that this peptide (IS1À/IS2þ) can derive from the cleavage of hMp84 at the C-terminus of IS1, similarly to the major cleavage of muscle p94, as described previously. Alternatively, p62 could derive from hMp78 cleaved inside the catalytic domain II (producing a virtually non-functional protease) or inside domain IV, in both cases in cleavage sites never described up to now in muscle p94.
Since both novel variants identified in melanoma cells have a lysinerich region (exon 15), i.e. a putative NLS, we performed western blot analysis in nuclear and post-nuclear extracts. Interestingly, uniquely in nuclear fractions, a peptide of $80 kDa (band D) appeared, which was very well evident by anti-IS2 antibody ( Figure 3E ) but also evident by anti-IS1 antibody ( Figure 3D) ; this means that such a peptide (IS2þ/IS1þ) derives from a little shortening of hMp84 at N-or C-terminus. The p62 peptide (band C) was present in both nuclear and post-nuclear fractions; instead, the $70 kDa peptide was present only in post-nuclear compartment, along with a further band lightly ,70 kDa. p84, rarely revealed in the whole extracts by anti-IS1 antibody, was undetectable by the same antibody in nuclear and post-nuclear fractions, possibly due to the longer time necessary for subcellular fractionation, which further elicits the intrinsic calpain degradation. The full-length hMp78 (IS1À/IS2þ) was never detected, neither in whole nor in subcellular extracts.
To assess the reliability of the commercial antibodies used, we performed additional western blots of melanoma cell extracts along with skeletal muscle extracts probed with both primary antibodies ( Figure 3F ). As expected, a major band of $62 kDa, as revealed by anti-IS2 antibody, was detected in melanoma cells as well as in muscle, probably corresponding to the autolytic fragment spanning from domain IIb to domain IV, as described in the literature (19, 21) . In muscle extracts, additional fragments (mainly IS2þ/IS1À) have been also revealed, thus confirming the complex cleavage/activation pattern of muscle calpain 3 suggested by others (19, 21) . In melanoma cells, along with p62 fragment shared with the muscle isoform, peptides larger than p62 were also detected; such a different cleavage pattern can be attributed to the different protein structure of calpain 3 melanoma variants and to a very different cellular context. In summary, the novel isoforms expressed in human melanoma cells undergo remarkable proteolytic events and, furthermore, a few cleavage products were found inside nuclei, consistently with the presence of a NLS in IS2 inset. On the basis of the biochemical studies on musclespecific p94, p62 should be a good candidate as a proteolytically active fragment: if p62 corresponds to the C-terminal moiety of hMp84 from domain IIb to domain IV, we can envisage that its reassociation with the N-terminal catalytic domain IIa, after IS1 excision, reconstitutes the active enzyme, similarly to muscle p94 (22) ; if p62 corresponds to hMp78 cleaved in domain IV, the catalytic site could be constitutively active, being hMp78 naturally devoid of IS1 inset. In cisplatin-treated cells, no qualitative change of the proteolytic patterns was observed but, on the whole, an increase of several cleavage forms confirmed the above-described increase of the major fragment p62. The subcellular localization of calpain 3 variants was also investigated by immunocytochemical analysis (Figure 4 ) using anti-IS1 or anti-IS2 antibody. Cells showed a reticular cytoplasmic positivity to both antibodies. Figure 2 ) and expressed as 2
ÀDDCt
. Fig. 2 . Schematic protein structure of the human muscle calpain 3 (p94), the ubiquitous human isoform (hUp84) and the novel variants hMp78 and hMp84 identified in human melanoma cell lines. Some exons are indicated with double-headed arrows inside IS1 and IS2 insets. Arrows out of the structures indicate the primers (described in Table I ) used in PCR or in real-time PCR.
Novel variants of muscle calpain 3 identified in human melanoma cells
With anti-IS1 antibody the staining had a slight preponderance around the nuclear region, whereas with anti-IS2 antibody the staining was more homogeneous throughout the cytoplasm, with distal cellular regions also positive. A striking difference was, however, observed in nucleoli, which were strongly positive in all melanoma cells, uniquely with anti-IS2 antibody. On the basis of the structure of calpain 3 isoforms and on the basis of western blot analysis performed on subcellular fractions, cytoplasmic stain might mirror both fulllength proteins plus the major p62 fragment (IS2þ/IS1À) and p70 fragment (IS1þ/IS2À), whereas nucleolar stain (revealed uniquely by anti-IS2) should correspond to the full-length hMp78 plus the major p62 fragment. The presence of an anti-IS1-positive band in western blot of the nuclear fraction, in the absence of any IS1-specific nuclear staining, can be attributed to a mild contamination by cytoplasmic perinuclear hMp84. Since the full-length proteins were hardly detected by western blots, we suggest that cleavage products of hMp84 and hMp78 (mainly the major form p62 deriving from hMp84), rapidly formed after translation, locate in the cytoplasm, enter nuclei and accumulate in nucleoli.
mRNA expression of hMp84 and hMp78 in human biopsies of melanocytic lesions By means of primers inside a region coding for IS2 insert (shared by both novel isoforms), we investigated by real-time PCR the presence and the expression levels of calpain 3 in human biopsies of benign nevi, dysplastic nevi, RGPMs, VGPMs and metastases ( Figure 5 ). All melanocytic biopsies showed the transcript, even if at variable extent. The amplified region (coding for IS2 insert) is also shared by three known splice variants of human p94 subfamily: the muscle-specific p94, the ubiquitous hUp84 and the lymphocytic variant. However, we infer that the transcript corresponds to the novel hMp84 and hMp78 variants. In fact (i) all tested human melanoma cell lines are negative for NS-coding exon 1, and all of them, as well as several bioptic melanocytic lesions ranging from benign nevi to metastases, are positive for AX2 (data not shown); this allows us to rule out the expression of the muscle-specific variant p94. The presence of AX2 could, however, suggest that the ubiquitous variant hUp84 is expressed, but (ii) the presence of both exon 15 and exon 16 in the IS2 coding region rules out the ubiquitous hUp84; furthermore, (iii) the presence of exon 15 rules out also the expression of the lymphocytic variant as well as a possible contamination of tumor-infiltrating lymphocytes in melanocytic lesions' tissues. The expression level of mRNA tended to be higher in benign nevi, dysplastic nevi and RGPM than in VGPM and metastases, although differences among groups were not significant, probably due to the high variability registered in VGPM and metastases and the relatively low number of cases. We, then, grouped together lesions representing early (dysplastic nevi þ RGPM) and late (VGPM þ metastases) stages of melanoma development and found a significant decrease of mRNA expression level in the latter when compared with the former (P , 0.01) and to benign nevi (P , 0.05).
Benign nevi, instead, did not significantly differ from dysplastic nevi and RGPM grouped together.
Discussion
In the present study, we report the identification of two novel splice variants (hMp78 and hMp84) of the muscle-specific calpain 3 (p94) subfamily, belonging to the large family of the cysteine proteases calpains. The sequence analysis of the entire cDNAs (deposited in GenBank under accession numbers EU91850 and EU91851) indicate (see Figure 2 ) that both variants share the first exon AX2 with the ubiquitous isoform hUp84 described by Kawabata et al. (12) , thus differing from the muscle-specific p94 for the absence of the typical NS coding region. Both novel variants differ from the ubiquitous variant in the presence of exon 15 (in the region corresponding to IS2 insert), an NLS that, in fact, allows the full-length and/or the cleaved proteins to enter nuclei and accumulate in nucleoli of melanoma cells. Although the role of this sequence has not been identified even in muscle-specific p94, it can be argued that this alternative splicing may produce a protein with a specific role in the nuclear compartment of human melanoma cells and possibly of other tumor cells. This subcellular localization might contribute to the malignant phenotype, taking in mind that in normal human tissues the ubiquitous hUp84 lacks exon 15. As concerns the presence of cleavage products in the nuclear compartment, we cannot discriminate in this experimental system if proteolysis occurs in extranuclear compartments or the full-length proteins enter nuclei, where the proteolysis could occur. To better understand these events, as well as to better identify the cleavage products, we will take advantage of cellular models overexpressing the variants. In cisplatin-treated Me665/2/21 cells, which are sensitive to different apoptotic triggers, a role of these calpain 3 variants in cell growth and survival is envisaged. In fact, in viable cells that showed only a decrease of cell proliferation or in viable cells committed to apoptosis but still adhering and showing minor signs of cell death, an increased gene expression and protein cleavage are observed; on the contrary, in frankly apoptotic cells, in which the transcription is generally impaired and a cascade of proteolytic events is irreversibly put in motion, decreased protein levels of the major peptide is observed. As far as apoptotic cell death is concerned, it is difficult at the moment to assess if the increased expression of calpain 3 variants, as observed in still viable cells, has a role in concurring or in opposing to the apoptotic machinery. However, it is a fact that the cotreatment with the conventional calpains' inhibitor, calpeptin, along with a partial protection from apoptosis, prevents p62 production. Moreover, from a speculative point of view, it is intriguing to note in vivo that in highly Novel variants of muscle calpain 3 identified in human melanoma cells aggressive lesions, namely in VGPMs and even more in metastases, a lower level of mRNA compared with benign nevi is observed. A decreased expression of the novel calpain 3 variants seems to characterize the advanced neoplasia, thus correlating with a phenotype commonly highly resistant toward apoptosis (25, 26) . On the whole, our observations suggest a proapoptotic role of calpain 3 in melanoma cells, along with the proapoptotic role of conventional calpains (1 and 2) that we have described previously (6) . The analysis of a larger series of cases and correlation with other clinicopathological parameters and patient follow-up could clarify the impact of calpain 3 in melanoma progression and its reliability as a novel prognostic marker.
In our experimental model, the decrease of p62 levels afforded by calpeptin is probably due to prevention of calpain 3 variants autolysis. The most simple explanation is that calpeptin can work as a direct inhibitor of calpain 3 activity, as observed in vitro by Ono et al. (27) by using high concentrations of calpeptin on purified mouse splice variant p94D. A more complex but interesting explanation could rely on the so-called 'calpain network' that is a cross talk between calpain 3 and the conventional calpains. Consistently with the view of calpain 3 as a possible regulator of conventional calpains, it has been demonstrated that p94D and p94 hydrolyze calpastatin, the endogenous inhibitor of conventional calpains (27) . Reciprocally, our data suggest that the conventional calpains could interfere (directly or indirectly) with calpain 3 and possibly promote its proteolysis, as indicated by the inhibitory effect of calpeptin.
In skeletal muscle cells, it has been showed that a defective proteolytic activity of calpain 3 due to diverse mutations in CAPN3 is responsible for limb-girdle muscular dystrophy type 2A (28) . Furthermore, a number of cytoskeletal and myofibrillar proteins (29) , bcatenin (30), IkBa (9), components of the protein synthesis system (31) and calpastatin (27) have been identified as proteolytic substrates of calpain 3 in overexpressing systems. As concerns possible substrates of calpain 3 variants in the specific context of human melanoma cells, the intracellular distribution of these variants in cytoplasm and in nucleoli suggest that they may play different roles at different sites. Undoubtedly, the nucleolar localization is very intriguing and worth to be explored, in the light of several recent investigations showing novel links between tumorigenesis and nucleolar function (reviewed in ref. 32 ). Long thought to be 'simply' the center of ribosome biogenesis, nucleoli are now being appreciated as more dynamic suborganelles containing along with several proteins of unknown function also oncoproteins and tumor suppressors (such as ARF, p53 and Mdm2) that can contribute to cellular fate under stress conditions. The presence of an activated protease in nucleolus can be in charge of proteolyzing crucial substrates sequestered in this compartment (either activating or inactivating them). Similarly to the nucleolar ARF-Mdm2-p53 feedback loop (33) , calpain 3 variants could proteolyze the negative regulator of p53, Mdm2, thus eliciting the nucleoplasmic stabilization of p53 and the expression of downstream proapoptotic genes. In the experimental model of the present study, such hypothesis is consistent with our previous results found in the same model (6) , showing a p53-dependent apoptosis that is mediated by conventional calpains.
As far as the muscle calpain 3 substrates, possibly shared with the novel variants, b-catenin can be an interesting candidate in melanoma cells since a constitutive activation of Wnt/b-catenin pathway (i.e. b-catenin in the nucleus) has been correlated to malignant transformation of melanocytes and to melanoma progression (34) . Similarly to muscle calpain 3 (30), melanocytic calpain 3 variants could be in charge of degrading the free cytoplasmic b-catenin, thus controlling the translocation to the nucleus, where b-catenin positively regulates transcription factors involved in cell proliferation, survival and motility. Interestingly, in very aggressive melanocytic lesions, where we have documented a very low expression of calpain 3 variants, such a control mechanism on b-catenin levels might be impaired.
In the present study, we suggest that the 'ectopic' expression of the novel calpain 3 isoforms hMp78 and hMp84 plays a role in melanoma cell biology and possibly in melanoma progression, and future studies of overexpression or silencing of these calpain 3 isoforms will give further insights on these issues, also in relation to specific substrates or interactive partners.
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